Dabur Pharma signs agreement with Combino Pharm

Dabur Pharma Ltd, on October 24, 2007 has announced that it has signed a supply & distribution agreement with Combino Pharm, one of Spain's leading generic Companies, to distribute and market generic oncology products in the Spanish market. The Spanish generic market is currently one of the fastest growing in the world. As per IMS, March 2006, the value of the Spanish generic market was approximately US$ 750 million, with an annual growth rate of 25%.

While the Company shall be responsible for registration and supply of products, Combino Pharm will handle the distribution, marketing & sales aspects. The Company, which already has approvals for three products in the UK, said that it expects to begin shipping the products to the Spanish market shortly and is awaiting MRP (Mutual Recognition Procedure) approval for its products from the Spanish Regulatory Authority.

Speaking on the occasion Ajay Kumar Vij, CEO of the Company said that "both Companies expect to benefit significantly from each other's strengths and the partnership should enable both to establish a significant presence in the Spanish oncology market".